1179 related articles for article (PubMed ID: 30824404)
1. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
Chanchlani N; Lin S; Bewshea C; Hamilton B; Thomas A; Smith R; Roberts C; Bishara M; Nice R; Lees CW; Sebastian S; Irving PM; Russell RK; McDonald TJ; Goodhand JR; Ahmad T; Kennedy NA;
Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):521-538. PubMed ID: 38640937
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Wang Y; Tsoulis DJ; MacDonald JK; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD003459. PubMed ID: 25099640
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
7. Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?
Lin S; Chanchlani N; Carbery I; Janjua M; Nice R; McDonald TJ; Bewshea C; Kennedy NA; Ahmad T; Selinger CP; Goodhand JR;
Aliment Pharmacol Ther; 2022 Sep; 56(5):783-793. PubMed ID: 35768996
[TBL] [Abstract][Full Text] [Related]
8. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Taylor K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
[TBL] [Abstract][Full Text] [Related]
9. Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.
Vasudevan A; Raghunath A; Anthony S; Scanlon C; Sparrow MP; Gibson PR; van Langenberg DR
Dig Dis Sci; 2019 Jun; 64(6):1622-1631. PubMed ID: 30560332
[TBL] [Abstract][Full Text] [Related]
10. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
Sazonovs A; Kennedy NA; Moutsianas L; Heap GA; Rice DL; Reppell M; Bewshea CM; Chanchlani N; Walker GJ; Perry MH; McDonald TJ; Lees CW; Cummings JRF; Parkes M; Mansfield JC; Irving PM; Barrett JC; McGovern D; Goodhand JR; Anderson CA; Ahmad T;
Gastroenterology; 2020 Jan; 158(1):189-199. PubMed ID: 31600487
[TBL] [Abstract][Full Text] [Related]
11. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
12. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Chande N; Townsend CM; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
14. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
Chande N; Patton PH; Tsoulis DJ; Thomas BS; MacDonald JK
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD000067. PubMed ID: 26517527
[TBL] [Abstract][Full Text] [Related]
15. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab for maintenance of remission in Crohn's disease.
Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Chande N; Tsoulis DJ; MacDonald JK
Cochrane Database Syst Rev; 2013 Apr; (4):CD000545. PubMed ID: 23633304
[TBL] [Abstract][Full Text] [Related]
19. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
20. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Louis E; Resche-Rigon M; Laharie D; Satsangi J; Ding N; Siegmund B; D'Haens G; Picon L; Bossuyt P; Vuitton L; Irving P; Viennot S; Lamb CA; Pollok R; Baert F; Nachury M; Fumery M; Gilletta C; Almer S; Ben-Horin S; Bouhnik Y; Colombel JF; Hertervig E;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):215-227. PubMed ID: 36640794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
